Hexarelin
A synthetic growth hormone–releasing peptide studied in early clinical research; not FDA-approved.
What it is
Hexarelin is among the most potent of the classic growth-hormone-releasing peptides, studied in the 1990s for GH release and, intriguingly, for direct cardiac effects that briefly made it a heart-research candidate.
Early human studies exist, but development stalled decades ago — partly because its strong GH stimulation shows desensitization with repeated use, and it nudges cortisol and prolactin more than its politer siblings. Never approved anywhere; prohibited in tested sport.
What researchers have actually studied it for
Growth-hormone release and cardiovascular effects in early clinical research from the 1990s; development never progressed to approval.
How it works
A six-amino-acid ghrelin-receptor agonist — the strongest acute GH releaser of the classic GHRP family in comparative studies. It also binds CD36, a receptor on heart and vascular tissue, the basis of its separate cardioprotective research thread.
Where it came from
Synthesized in the early 1990s in the GHRP wave that followed ghrelin-pathway discoveries, hexarelin generated genuine academic interest — including small human studies on cardiac function — before receptor desensitization and industry pivots shelved it. It persists as gray-market inventory with a vintage literature.
What the research record actually contains
- 1990s human pharmacology: potent acute GH release, with documented attenuation over weeks of repeated dosing.
- Small human and animal studies on cardiac contractility and ischemia via CD36 — never advanced.
- No controlled trials on body composition or any marketed wellness outcome.
What's known about risks
Beyond acute-study tolerability, unknowns dominate: its cortisol/prolactin nudge, receptor desensitization, and untested chronic use. The cardiac binding cuts both ways — interesting mechanism, uncharacterized long-term meaning.
Where it stands legally
Never approved; research-chemical channel only. Prohibited in tested competition.
Worth asking a licensed provider
- 1.If GH-axis therapy is the goal, why this shelved compound over options with active medical use?
- 2.What does receptor desensitization mean for any sustained plan?
- 3.What monitoring would make sense given its broader hormonal footprint?